The Traws Pharma, Inc. (NASDAQ: TRAW) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. These documents offer detailed information on Traws’ clinical-stage antiviral programs, financial position, governance and executive compensation, and they complement the company’s press releases.
Through periodic reports such as the Form 10-K and proxy statements, Traws describes its business focus on developing investigational oral small molecule antivirals for respiratory viral diseases, including COVID-19, Long COVID, bird flu and seasonal influenza. The definitive proxy statement (DEF 14A) outlines board structure, incentive compensation plans and matters submitted to stockholders, while also providing context on corporate governance and director elections.
Current reports on Form 8-K, several of which are referenced in the provided data, document material events such as interim clinical data announcements for ratutrelvir, approval to proceed with Phase 2 COVID-19 studies, dosing of the first Phase 2 subjects, quarterly earnings releases, option and restricted stock unit grants to executives, and the appointment of new board members and officers. These filings also confirm that Traws’ common stock is listed on The Nasdaq Stock Market LLC under the symbol TRAW.
Investors and analysts can use this page to review how Traws reports on its clinical progress with ratutrelvir and tivoxavir marboxil, its legacy oncology programs rigosertib and narazaciclib, and its financial results and capital structure. Forms related to executive and director compensation, incentive plans and governance changes provide additional insight into how the company aligns management incentives with its development priorities.
Stock Titan enhances access to these filings by organizing them chronologically and by form type, and by offering AI-powered summaries that explain the key points of lengthy documents such as annual reports, quarterly updates and 8-Ks. This allows users to quickly understand the significance of new filings, track trends in Traws’ disclosures and identify items such as clinical milestones, financing arrangements or changes in leadership that may be important for evaluating TRAW stock.
Traws Pharma, Inc. files a resale prospectus registering up to 35,897,514 shares of Common Stock for resale by selling stockholders. The shares include 4,993,412 Initial Shares and up to 30,904,102 shares issuable upon exercise of Pre-Funded Warrants and Series A, B and C Warrants. The Company is not selling any shares under this prospectus and will receive no proceeds from resale; however, the Company would receive cash proceeds only if Warrants are exercised for cash. The prospectus notes a beneficial ownership limit on exercises (4.99% or, optionally, 9.99%) and describes warrant exercise conditions tied to regulatory milestones, shareholder approval and registration effectiveness. Shares outstanding were 15,150,669 as of April 24, 2026 as used for the selling-stockholder table.
Traws Pharma, Inc. reports that Perceptive Advisors and related parties hold an aggregate 6.1% stake via 979,815 warrants exercisable into Common Stock. The ownership percentage is calculated using 15,150,669 shares outstanding as of April 24, 2026. The Warrants are exercisable subject to the Beneficial Ownership Limitation, which prevents exercise if doing so would increase beneficial ownership above 9.99%.
Traws Pharma discloses a 6.4% stake held by Squadron Master Fund LP and affiliated filers. The Schedule 13G/A (Amendment No. 3) reports that Squadron Master Fund LP, Squadron Capital Management LLC, Matthew Sesterhenn and William Blank each have shared voting and dispositive power over 511,714 shares.
The filing bases the ownership percentage on 7,990,867 shares outstanding as of November 10, 2025, per the issuer's Form 10-Q. Signatures on the amendment are dated 05/15/2026.
Traws Pharma, Inc. reported a first-quarter 2026 net loss of $7.1 million, reversing net income a year earlier, as it ramped investment in its respiratory virus pipeline. Revenue was zero versus $57,000 in 2025, while research and development spending nearly doubled to $4.9 million, driven by work on ratutrelvir, tivoxavir marboxil and TRX01.
General and administrative costs fell to $2.0 million. Cash and cash equivalents were $3.1 million at March 31, 2026, against an accumulated deficit of $647.1 million and a working capital deficit of $7.9 million. Management states there is substantial doubt about the company’s ability to continue as a going concern without new capital.
In April 2026, Traws closed an equity financing with upfront gross proceeds of $10.0 million and issued milestone-based and common warrants that could raise up to an additional $50.0 million if fully exercised. The company also continued a legal arbitration with a former executive and detailed progress across its clinical programs, including Phase 2 development for ratutrelvir and ongoing regulatory interactions for tivoxavir marboxil.
Traws Pharma, Inc. reported Q1 2026 results showing a net loss of $7.1 million, or $0.53 per basic and diluted share, compared with net income of $21.5 million a year earlier, largely reflecting changes in warrant liability and higher R&D spending.
Revenue was $0.0 million versus $57,000 in Q1 2025. Research and development expense rose to $4.9 million from $2.5 million, while general and administrative expense declined to $2.0 million from $2.8 million.
The company highlighted an up to $60 million private investment in public equity, including $10 million received at closing and additional potential proceeds from milestone-based and three-year warrants, which together with existing cash are expected to fund operations, including a human influenza challenge trial for tivoxavir marboxil, into Q1 2027.
Traws Pharma, Inc. files a registration on Form S-3 to permit resale by selling stockholders of up to 35,897,514 shares of its common stock. The shares comprise Initial Shares and shares issuable upon exercise of Pre-Funded Warrants and Series A, B and C Warrants.
The prospectus states the company will not receive proceeds from resales by selling stockholders; the company would receive cash only if the Warrants are exercised for cash. The filing notes 15,150,669 shares outstanding as of April 24, 2026 for table calculations and lists listing on NASDAQ under TRAW.
OrbiMed Advisors LLC and OrbiMed Capital GP VIII LLC filed Amendment No. 3 to report beneficial ownership of 1,876,198 Traws Pharma Shares, or 11.9% of the class. This stake includes 1,203,260 Shares held by OrbiMed Private Investments VIII, LP and 672,938 Shares issuable from presently convertible Series C Non-Voting Convertible Preferred Stock.
OPI VIII also holds 96,348 Pre-Funded Warrants, 96,348 2024 Series A Warrants and 2,988,645 2026 Warrants, which are excluded from the 1,876,198-share figure. OrbiMed entities purchased securities in a December 2024 offering and an April 2026 private placement and entered into a support agreement and a registration rights agreement with the issuer.
Traws Pharma, Inc. filed Amendment No. 1 to its Form 10-K for the year ended December 31, 2025 to add Part III information on directors, executive officers, compensation, ownership and related-party matters because a proxy statement will not be filed within 120 days. The amendment does not update prior financial statements or other disclosures.
The filing details board composition, committee memberships, independence determinations, director and executive pay arrangements, equity awards, significant shareholders, related-party R&D and licensing agreements, and auditor fees, while affirming existing governance policies such as the code of conduct and insider trading policy.
Entities affiliated with OrbiMed increased their indirect stake in Traw Pharma through a private placement. OrbiMed Private Investments VIII LP acquired 597,729 shares of common stock at $1.67 per share and Series A, B and C warrants exercisable for up to 2,988,645 shares at $1.673 per share. Following the purchase, indirect holdings reported for common stock rose to 1,203,250 shares. The transactions closed on April 16, 2026, and the reporting entities disclaim beneficial ownership beyond their pecuniary interest.